MDT240816C60000
- 17.60
- 0.000.00%
Medtronic Newsroom
TD Cowen Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $95
Medtronic Upgraded at UBS on Diabetes Turnaround
UBS Upgrades Medtronic(MDT.US) to Hold Rating, Raises Target Price to $90
Analysts Offer Insights on Healthcare Companies: Evotec AG (EVO), Medtronic (MDT) and Cardinal Health (CAH)
Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Medtronic (MDT)
Stifel Downgrades Medtronic, Citing Delayed Progress
Stifel Maintains Medtronic(MDT.US) With Hold Rating, Maintains Target Price $85
Medtronic Analyst Ratings
Stifel Downgrades Medtronic to Hold From Buy, Adjusts Price Target to $85 From $100
Stifel Downgrades Medtronic(MDT.US) to Hold Rating, Cuts Target Price to $85
Stifel Downgrades Medtronic to Hold, Cites Growth Outlook
Medtronic Analyst Ratings
Wells Fargo Sticks to Their Buy Rating for Medtronic (MDT)
Wells Fargo Maintains Medtronic(MDT.US) With Buy Rating, Announces Target Price $105
Buy Rating Affirmed for Medtronic on Recent FDA Approvals and Competitive Market Positioning
DexCom Reaches a Multi-year Low as Downgrades Follow Guidance Cut
Truist Securities Maintains Hold on Medtronic, Lowers Price Target to $85
Medtronic Analyst Ratings
Truist Trims Price Target on Medtronic to $85 From $88, Keeps Hold Rating
Medtronic's Stable Outlook and Growth Prospects Reinforce Buy Rating